PLAU and cancer: Our overall results demonstrate that the production of uPAR-targeted, saporin-based recombinant fusion ATF-SAP that has significant therapeutic potential in the treatment of human cancers can be efficiently produced into a 2 l bioreactor and that the obtained chimeric protein is has full cytotoxic activity against human cancer cells.